OraSure Technologies (NASDAQ:OSUR) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of OraSure Technologies (NASDAQ:OSUR) from a sell rating to a hold rating in a research note released on Saturday.

Separately, Weiss Ratings raised OraSure Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, June 4th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Reduce” and an average price target of $3.00.

OraSure Technologies Price Performance

Shares of NASDAQ:OSUR opened at $3.96 on Friday. The company has a market capitalization of $272.65 million, a P/E ratio of -3.81 and a beta of 1.01. OraSure Technologies has a 1 year low of $2.08 and a 1 year high of $4.58. The business’s 50 day simple moving average is $4.10 and its 200 day simple moving average is $3.34.

Insider Transactions at OraSure Technologies

In other news, Director Steven Kyle Boyd bought 25,000 shares of the company’s stock in a transaction on Thursday, May 14th. The stock was purchased at an average cost of $2.99 per share, for a total transaction of $74,750.00. Following the completion of the transaction, the director owned 113,462 shares of the company’s stock, valued at $339,251.38. This trade represents a 28.26% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available at this link. 4.70% of the stock is currently owned by insiders.

Institutional Trading of OraSure Technologies

Hedge funds have recently made changes to their positions in the company. Kotler Kevin acquired a new position in shares of OraSure Technologies in the fourth quarter valued at approximately $4,359,000. Millennium Management LLC boosted its position in OraSure Technologies by 71.1% during the 3rd quarter. Millennium Management LLC now owns 2,112,507 shares of the medical instruments supplier’s stock worth $6,781,000 after buying an additional 878,151 shares during the period. Yorkville Advisors Global LP acquired a new stake in OraSure Technologies during the 1st quarter worth approximately $1,905,000. Archon Capital Management LLC bought a new stake in OraSure Technologies during the 4th quarter worth approximately $1,388,000. Finally, Cannell Capital LLC grew its holdings in OraSure Technologies by 33.7% during the 2nd quarter. Cannell Capital LLC now owns 1,864,989 shares of the medical instruments supplier’s stock worth $5,595,000 after acquiring an additional 470,536 shares during the last quarter. 93.50% of the stock is owned by institutional investors and hedge funds.

OraSure Technologies Company Profile

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.